COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer30/09/2025
-   
  Coloplast A/S - Financial Calendar 2025-2630/09/2025
-   
  The MUHC Foundation’s Inaugural Breakthrough Run Wins Big at the Montreal Marathon30/09/2025
-   
  La première édition de la Course vers la Percée de la Fondation du CUSM remporte un franc succès lors du Marathon de Montréal30/09/2025
-   
  September 2025 Letter to Shareholders30/09/2025
-   
  Vivex Biologics Treats First Patient in its Restore Trial Evaluating VIA Disc NP™ for Patients with Degenerative Disc Disease30/09/2025
-   
  Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device30/09/2025
-   
  Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)30/09/2025
-   
  Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access30/09/2025
-   
  Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services30/09/2025
-   
  SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update30/09/2025
-   
  Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia30/09/2025
-   
  Branded Legacy, Inc. Announces Provisional Patent Filing by BioLegacy for Disruptive Air-Driven Intranasal Platform Targeting Multi-Billion-Dollar Global Therapeutics Market30/09/2025
-   
  Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial30/09/2025
-   
  Cannabix Technologies Announces First Sale of BreathLogix Alcohol Screening Device to Maritime Market30/09/2025
-   
  Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer30/09/2025
-   
  Artelo Biosciences Announces Pricing of $2.0 Million Public Offering30/09/2025
-   
  FDA Clears OsteoProbe® (K250216): First-Ever Device Indication for Measuring Bone Material Strength30/09/2025
-   
  STRATA Skin Sciences Receives Continued Validation for its Personalized Approach with New Published Study Highlighting XTRAC® Excimer Laser Treatment Combined with a Topical Drug in Psoriasis30/09/2025
Pages